

JOURNAL OF CLINICAL RESEARCH BEST PRACTICES

Vol. 5, No. 7, July 2009

"Can You Handle the Truth?"

"Drugs in Development: From Pipeline to Market 2009"

PharmaLive.com, 2009, 140 pages, \$485

Review by Norman M. Goldfarb

"Drugs in Development: From Pipeline to Market 2009" is a comprehensive directory of drug companies and drugs from Phase I through FDA approval. The report provides the name, indication, development phase, and company (with website) for 2,333 drugs in 10 therapeutic areas under development by about 650 companies, as well as 70 drugs approved from June 2008 through April 2009 and 220 drugs awaiting approval. Cancer (831 drugs), CNS (329 drugs), and infections (229 drugs) are the most active areas of development. Drugs in development for pain and inflammation increased 71% to 204 from 2008. Cardiovascular drugs decreased 9% to 191 from 2008. In 2008, FDA approved 21 new molecular entities and three biologic license applications, up slightly from previous years. Approval numbers in 2009 are running at about the same rate.

This report is useful for competitive intelligence, for sites looking for clinical studies, and for other service providers looking for clients. Information sources include www.clinicaltrials.gov, interviews, and corporate websites, press releases, annual reports, and other documents.

The book consists of 13 chapters:

- Introduction
- Top company R&D spenders in 2008
- Number of drugs in top 10 therapeutic categories
- 2009 vs. 2008 number of drugs comparison
- Companies by therapeutic category
- Approved medicines
- Awaiting approval
- Drugs in Phase III clinical trials
- Drugs in Phase II/III clinical trials
- Drugs in Phase II clinical trials
- Drugs in Phase I/II clinical trials
- Drugs in Phase I clinical trials
- Alphabetical listing of medicines approved and in development

The report is available at http://www.pharmalive.com/special_reports.

Reviewer

Norman M. Goldfarb is Managing Director of First Clinical Research LLC, a provider of clinical research best practices information, consulting and training services. Contact him at 1.650.465.0119 or ngoldfarb@firstclinical.com.